GLATIRAMER ACETATE
Clinical safety rating: safe
Animal studies have demonstrated safety
Glatiramer acetate is a mixture of synthetic polypeptides composed of four amino acids (L-glutamic acid, L-lysine, L-alanine, and L-tyrosine). Its mechanism is not fully understood but is thought to modulate the immune system by inducing antigen-specific suppressor T cells, shifting the cytokine profile from pro-inflammatory (Th1) to anti-inflammatory (Th2), and promoting neuroprotection through increased brain-derived neurotrophic factor (BDNF) production.
| Metabolism | Glatiramer acetate is a polypeptide mixture; it is largely hydrolyzed locally at the injection site and systemically by proteolysis. No specific hepatic cytochrome P450 enzymes are involved. Metabolites are excreted renally and via feces. |
| Excretion | Primarily renal excretion of intact glatiramer acetate and its metabolites; minimal biliary/fecal elimination. Exact percentages not established due to extensive metabolism. |
| Half-life | Terminal half-life is approximately 1-2 hours for the parent compound; however, clinical effects persist for days to weeks due to immunological mechanisms (e.g., antigen-specific T-cell modulation). |
| Protein binding | Approximately 80-90% bound to plasma proteins (mainly albumin). |
| Volume of Distribution | Approximately 0.5-2 L/kg, suggesting distribution into extracellular fluid and some tissue binding. |
| Bioavailability | Subcutaneous: Approximately 100% relative to intravenous administration (as determined by total glatiramer acetate species in plasma). |
| Onset of Action | Subcutaneous: Clinical benefit (reduction in relapse rate in multiple sclerosis) typically observed after 3-6 months of daily administration; no immediate effect. |
| Duration of Action | Duration of clinical effect is sustained with continuous daily dosing; withdrawal leads to gradual loss of benefit over weeks to months. |
20 mg subcutaneously once daily for relapsing forms of multiple sclerosis.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment; glatiramer acetate is not renally cleared. |
| Liver impairment | No dose adjustment required for hepatic impairment; no studies in Child-Pugh classes. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; clinical studies did not include sufficient elderly patients. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug reactions Can cause immediate post-injection reaction (flushing chest pain palpitations).
| Breastfeeding | Glatiramer acetate is a large polypeptide; minimal transfer into breast milk is expected. M/P ratio not determined. Considered compatible with breastfeeding by the American Academy of Neurology. |
| Teratogenic Risk | No increased risk of major birth defects or miscarriages based on large prospective cohort studies. No evidence of teratogenicity in animal studies. No specific trimester risks identified. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Common Effects | Injection site reactions |
| Serious Effects |
["History of hypersensitivity to glatiramer acetate or mannitol"]
| Precautions | ["Immediate post-injection reaction (flushing, chest tightness, palpitations, anxiety, dyspnea) occurs in up to 15% of patients; typically self-limited but may be alarming","Lipoatrophy and skin necrosis at injection sites with repeated administration","Immune-mediated reactions: anaphylaxis, angioedema, and hypersensitivity reactions (rare)","May increase the risk of infections due to immunomodulatory effects","Pancreatitis has been reported (rare)","Possible liver injury (elevated transaminases) in postmarketing reports"] |
| Food/Dietary | No known food interactions. Grapefruit and other CYP450-modulating foods are not relevant as glatiramer acetate is not metabolized by CYP450 enzymes. No dietary restrictions required. |
Loading safety data…
| No specific monitoring required. Standard pregnancy monitoring. No fetal monitoring indicated for glatiramer acetate. |
| Fertility Effects | No known adverse effects on fertility in animal studies. No human data suggesting impairment of fertility. |
| Clinical Pearls | Glatiramer acetate is an immunomodulator used for relapsing forms of multiple sclerosis. It is not a first-line therapy for rapidly progressive disease. Injection site reactions are common; rotate sites and avoid injecting into scarred or tender areas. A transient post-injection systemic reaction (flushing, chest tightness, palpitations, anxiety) may occur within minutes, typically resolves spontaneously within 30 minutes. Do not switch between 20 mg/mL daily and 40 mg/mL three times weekly without dose equivalence adjustment. Monitor for lipoatrophy and skin necrosis at injection sites. |
| Patient Advice | Instruct patients on proper subcutaneous injection technique and site rotation (abdomen, arms, hips, thighs). · Advise that injection site reactions (redness, pain, swelling) are common and usually self-limiting. · Explain the possibility of a post-injection systemic reaction (flushing, chest tightness, rapid heartbeat, anxiety) that typically resolves without treatment. · Emphasize not to interrupt therapy without consulting their neurologist, as discontinuation may increase relapse risk. · Store glatiramer acetate vials/syringes in the refrigerator (2-8°C); allow to warm to room temperature for 20 minutes before injection. · Discard any unused solution; do not reuse syringes or vials. |